TITLE

Managing patients who are overweight or obese

AUTHOR(S)
Shephard, Valerie E.
PUB. DATE
July 2006
SOURCE
Practice Nurse;7/7/2006, Vol. 32 Issue 1, p42
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The article provides information on the management of overweight patients. To lose weight, on a daily basis an individual needs to reduce the energy content of the food and drink they consume, increase the energy they use, or both. The British Department of Health has published a new set of practical tools to help practice nurses and other health professionals encourage patients to lose weight and improve their health. Orlistat and sibutramine are approved for prescription to people who are obese.
ACCESSION #
21662031

 

Related Articles

  • Orlistat, sibutramine, and rimonabant reduce weight in overweight and obese persons. Kanaya, Alka M. // ACP Journal Club;Mar/Apr2008, Vol. 148 Issue 2, p24 

    The article focuses on 30 randomized controlled trials (RCTs) investigating the long-term efficacy of antiobesity drugs (AODs) for reducing weight and improving health status in overweight or obese persons. Trials found out that orlistat, sibutramine and rimonabant reduces weight and improve...

  • Pharmacotherapy of Obesity: An Update. Schurgin, Sunita; Siegel, Richard D. // Nutrition in Clinical Care;Jan-Apr2003, Vol. 6 Issue 1, p27 

    There has been an epidemic of obesity in the last decade, In spite of the rising numbers of people who are overweight and obese, medical treatment of obesity is currently where medical treatment of hypertension was in the 1950s with only two Food and Drug Administration-approved medications for...

  • DRUGS FOR OBESITY. Mead, Mike // Practice Nurse;9/10/2004, Vol. 28 Issue 4, p64 

    Focuses on prescription drugs available to help obese patients to lose weight. Clinical indications of Sibutramine and Orlistat; Contraindications and side effects of the drugs; Importance of monitoring patients who are taking drug therapy.

  • Efficacy and Tolerability of the Association of Sibutramine and Orlistat for Six Months in Overweight and Obese Patients. Halpern, Alfredo; Pepe, Renata B.; Monegaglia, Ana Paola; Beyruti, Mônica; de Melo, Maria Edna; Mancini, Marcio C. // Journal of Obesity;2010, Vol. 2010, p1 

    Objective. To assess the efficacy and tolerability of the association sibutramine (10-20 mg/day) and orlistat (120 mg 2-3 times a day) in the treatment of obesity in a six-month open trial. Methods. 446 overweight and obese patients who sought treatment for obesity in a private clinic were...

  • Pharmacotherapy for the treatment of obesity has only modest benefits and should be used in combination with lifestyle modifications. Adis International Limited // Drugs & Therapy Perspectives;Jan2006, Vol. 22 Issue 1, p7 

    The article discusses the elements of treatment of obesity. This article suggests pharmacotherapy only for obese patients with a severe weight problem who have failed to lose weight by a reasonable trial of other means. Pharmacotherapies that are approved for the management of weight loss are...

  • Poster session: Track 6, Psychological, social and economic issues.  // International Journal of Obesity & Related Metabolic Disorders;May2003 Supplement, Vol. 27, pS146 

    International Journal of Obesity (2003) 27, S146-S156. doi:10.1038/sj.ijo.0802364

  • Poster session: Track 4, Management.  // International Journal of Obesity & Related Metabolic Disorders;May2003 Supplement, Vol. 27, pS97 

    International Journal of Obesity (2003) 27, S97-S127. doi:10.1038/sj.ijo.0802362

  • What Cardiologists Need to Know About Obesity. Purcell, Henry; Sheppard, Mary // Current Medical Literature: Interventional Cardiology Monitor;2006, Vol. 13 Issue 4, p93 

    The article provides information on obesity. It states that approximately two-thirds of the population of England are overweight or obese. Mechanisms that are responsible for the development of obesity-related hypertension, including increased sympathetic adrenergic activity, are enumerated. It...

  • What extent of weight loss can benefit the health-related quality of life in motivated obese Chinese? Chih-Hsing Wu; Hui-Ching Kuo; Chin-Sung Chang; Lung Yu // Asia Pacific Journal of Clinical Nutrition;Sep2009, Vol. 18 Issue 3, p423 

    Background: A clinical significant improvement in health-related quality of life (HRQOL) is one of the main goals of weight control. Objective: To reveal the extent of weight loss on changes of HRQOL in obese Chinese. Design: A total of 119 motivated obese adults (BMI: 33.5 ± 0.4 kg/m2)...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics